Cargando…
Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland
BACKGROUND: Calprotectin (S100A8/A9 or myeloid-related protein 8/14) is a heterodimeric S100 complex expressed in leukocytes. Calprotectin participates in development of the inflammatory response by binding to receptors for advanced glycation end-products (RAGE) and Toll-like receptors (TLR). The cl...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290428/ https://www.ncbi.nlm.nih.gov/pubmed/35821629 http://dx.doi.org/10.12659/MSM.936534 |
_version_ | 1784748897963343872 |
---|---|
author | Homa-Mlak, Iwona Mazurek, Marcin Majdan, Aleksandra Mlak, Radosław Majdan, Maria Mełecka-Massalska, Teresa |
author_facet | Homa-Mlak, Iwona Mazurek, Marcin Majdan, Aleksandra Mlak, Radosław Majdan, Maria Mełecka-Massalska, Teresa |
author_sort | Homa-Mlak, Iwona |
collection | PubMed |
description | BACKGROUND: Calprotectin (S100A8/A9 or myeloid-related protein 8/14) is a heterodimeric S100 complex expressed in leukocytes. Calprotectin participates in development of the inflammatory response by binding to receptors for advanced glycation end-products (RAGE) and Toll-like receptors (TLR). The clinical activity of systemic lupus erythematosus (SLE) is evaluated using the Systemic Lupus International Collaborating Clinics (SLICC) criteria and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). This Polish single-center case-control study aimed to evaluate serum levels of calprotectin as a rapid diagnostic biomarker of SLE (59 patients with SLE were compared with 52 healthy controls). MATERIAL/METHODS: Calprotectin concentration was measured with the use of enzyme-linked immunosorbent assay (ELISA). The SLE activity of the patients was assessed by the SLEDAI scale. Statistical analysis of the results was carried out using MedCalc 15.8 software. P<0.05 was considered statistically significant. RESULTS: A significantly higher concentration of calprotectin was found in the study group compared to the control group (medians: 3.11 vs 2.45 ng/ml; P=0.0013). We found that calprotectin has high sensitivity (89.83%) and specificity (53.85%) in differentiating between SLE patients and healthy volunteers. We found that calprotectin has very high sensitivity (100%) and specificity (82.46%) in detection of patients with moderate and severe SLE assessed using SLEDAI. CONCLUSIONS: Consistent with previous studies, serum calprotectin level was revealed to have potential as a rapid diagnostic biomarker of disease activity in patients with SLE. |
format | Online Article Text |
id | pubmed-9290428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92904282022-07-28 Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland Homa-Mlak, Iwona Mazurek, Marcin Majdan, Aleksandra Mlak, Radosław Majdan, Maria Mełecka-Massalska, Teresa Med Sci Monit Clinical Research BACKGROUND: Calprotectin (S100A8/A9 or myeloid-related protein 8/14) is a heterodimeric S100 complex expressed in leukocytes. Calprotectin participates in development of the inflammatory response by binding to receptors for advanced glycation end-products (RAGE) and Toll-like receptors (TLR). The clinical activity of systemic lupus erythematosus (SLE) is evaluated using the Systemic Lupus International Collaborating Clinics (SLICC) criteria and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). This Polish single-center case-control study aimed to evaluate serum levels of calprotectin as a rapid diagnostic biomarker of SLE (59 patients with SLE were compared with 52 healthy controls). MATERIAL/METHODS: Calprotectin concentration was measured with the use of enzyme-linked immunosorbent assay (ELISA). The SLE activity of the patients was assessed by the SLEDAI scale. Statistical analysis of the results was carried out using MedCalc 15.8 software. P<0.05 was considered statistically significant. RESULTS: A significantly higher concentration of calprotectin was found in the study group compared to the control group (medians: 3.11 vs 2.45 ng/ml; P=0.0013). We found that calprotectin has high sensitivity (89.83%) and specificity (53.85%) in differentiating between SLE patients and healthy volunteers. We found that calprotectin has very high sensitivity (100%) and specificity (82.46%) in detection of patients with moderate and severe SLE assessed using SLEDAI. CONCLUSIONS: Consistent with previous studies, serum calprotectin level was revealed to have potential as a rapid diagnostic biomarker of disease activity in patients with SLE. International Scientific Literature, Inc. 2022-07-13 /pmc/articles/PMC9290428/ /pubmed/35821629 http://dx.doi.org/10.12659/MSM.936534 Text en © Med Sci Monit, 2022 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Clinical Research Homa-Mlak, Iwona Mazurek, Marcin Majdan, Aleksandra Mlak, Radosław Majdan, Maria Mełecka-Massalska, Teresa Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland |
title | Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland |
title_full | Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland |
title_fullStr | Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland |
title_full_unstemmed | Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland |
title_short | Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland |
title_sort | serum calprotectin – a net product – as a biomarker of disease activity in patients with systemic lupus erythematosus: a single-center case-control study from poland |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290428/ https://www.ncbi.nlm.nih.gov/pubmed/35821629 http://dx.doi.org/10.12659/MSM.936534 |
work_keys_str_mv | AT homamlakiwona serumcalprotectinanetproductasabiomarkerofdiseaseactivityinpatientswithsystemiclupuserythematosusasinglecentercasecontrolstudyfrompoland AT mazurekmarcin serumcalprotectinanetproductasabiomarkerofdiseaseactivityinpatientswithsystemiclupuserythematosusasinglecentercasecontrolstudyfrompoland AT majdanaleksandra serumcalprotectinanetproductasabiomarkerofdiseaseactivityinpatientswithsystemiclupuserythematosusasinglecentercasecontrolstudyfrompoland AT mlakradosław serumcalprotectinanetproductasabiomarkerofdiseaseactivityinpatientswithsystemiclupuserythematosusasinglecentercasecontrolstudyfrompoland AT majdanmaria serumcalprotectinanetproductasabiomarkerofdiseaseactivityinpatientswithsystemiclupuserythematosusasinglecentercasecontrolstudyfrompoland AT mełeckamassalskateresa serumcalprotectinanetproductasabiomarkerofdiseaseactivityinpatientswithsystemiclupuserythematosusasinglecentercasecontrolstudyfrompoland |